Regulatory Approvals

Recon: FDA approves Stada’s Lucentis biosimilar; Lilly says ‘triple-G’ candidate bests Ozempic in diabetes

By

Regulatory Approvals — Recon: FDA approves Stada’s Lucentis biosimilar; Lilly says ‘triple-G’ candidate bests Ozempic in diabetes  RAPS

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. October 29, 2026.

By

Related Post

Regulatory Approvals

Zoetis (ZTS) Wins FDA Approval For Convenia RTU, Is The Undervaluation Case Still Intact?

Regulatory Approvals

FDA approves dostarlimab (Jemperli) for certain patients with locally advanced rectal cancer

Regulatory Approvals

After 30 Years, FDA Approves First-Ever Drug For a Rare Neurological Disorder

Financial News For All

Labor

Teamsters strike resumes for three Orange County departments

Labor

Orange County waste and public works employees are back on strike

Labor

A Global Port Strike Could Freeze $2 Billion in Freight

Labor

News 5 Cleveland affected by nationwide layoffs at parent company Scripps